A biopharmaceutical company dedicated to the development of novel diagnostic

1
Osta Biotechnologies Inc.
Corporate Fact Sheet October 2007
 
A biopharmaceutical company dedicated to the
development of novel diagnostic and therapeutic
products in the areas of Cancer Alzheimers
Disease Osteoporosis Osteoarthritis XLH
Company Profile
Osta Biotechnologies Inc. (OstaTSX-VOBI) is a
life sciences firm, primarily focused on the
development of novel diagnostic and therapeutic
products for Alzheimers disease, cancer, XLH,
osteoporosis and osteoarthritis. Based in
Montreal, Ostas scientific team is comprised of
world-renowned clinicians, oncologists, bone
biologists and neurologist with a proven track
record of identifying, patenting, and developing
products and technologies for diseases affecting
the aging population. Ostas Alzheimers
disease diagnostic therapeutic products could
potentially represent a breakthrough in detecting
treating the neurodegenerative disease at an
early stage. Ostas anti-cancer drugs belong to
a novel class of compounds that have been shown
to be safe and very effective against a number of
drug resistant, aggressive and metastatic
tumors. Osta has a rich pipeline of validated
targets for the development of novel prognostic
test for osteoporosis and therapeutic agents for
osteoporosis, osteoarthritis and XLH
Management Dr. Ajay Gupta, PhD. Founder,
Chairman and CEO Dr. Andrew Karaplis, M.D.,
PhD., FRCP(C) Co-founder, President CSO Dr.
David Goltzman M.D. Senior V.P. RD, Chairman
SAB, CAB Dr. Michael Munzar M.D. V.P. Medical
Regulatory Affairs Mr. Robert Ohayon V.P.
Business Development Commercialization Mr.
William Waks, CA Chief Financial Officer Mr.
Alain Geahchan Director of Operations Fast
Facts   TSXV Symbol OBI Fiscal Year End
December 31 Shares outstanding (basic)
34,706,196 Legal Counsel Heenan
Blaikie Auditors WSBG s.e.n.c.r.l.

• Investment Highlights
• Solid clinical data on blood test for
  Alzheimers disease
• No commercial blood-based biological markers
  currently exist for Alzheimers disease
• Solid pre-clinical data on a new class of
  cancer drugs, IND filing anticipated in 2009
• Rich pipeline of validated novel therapeutics
  for osteoporosis, osteoarthritis and XLH
• Solid and growing intellectual property
  portfolio
• Attractive market capitalization of 10.4
  million
• World-renowned clinicians, oncologists, bone
  biologists and neurologist with proven track
  records

2
Osta Biotechnologies Inc.
Corporate Fact Sheet October 2007
RD Products
Lead Products Cancer Therapeutics Osta is
developing a novel class of chemotherapeutic
agents that could be used as adjuvant
therapeutics to treat aggressive metastatic,
invasive and drug resistant tumours. Solid
pre-clinical data obtained to date has shown the
safety and effectiveness of Ostas drugs for the
treatment of a number of highly aggressive,
metastatic and drug resistant tumors. Diagnostic
Blood Test for Alzheimers Disease (AD)
Currently, there are no commercial blood-based
biological markers with proven effectiveness in
diagnosing AD. Clinical studies involving 81
subjects to-date have shown that Ostas biomarker
distinguishes patients with AD patients with
mild cognitive impairment from patients with
Parkinsons disease and normal elderly
controls. Therapeutic Agent for Alzheimers
Disease (AD) Currently at pre-clinical stage,
Ostas small molecule AD therapeutic product is
based on a novel class of AD drugs and targets a
very early stage in AD pathology.  
Pipeline Osteoporosis Prognostic test Osta is
developing a novel blood test for assessing the
risk of developing low bone mass and osteoporosis
and has obtained solid clinical data in a total
of 264 males and 33 females to date. Osteoporosis
Therapeutic (OP) Currently at pre-clinical
stage, Osta is developing novel bone anabolic
agents for the treatment of OP. Osteoarthritis
Therapeutic (OA) Currently at pre-clinical stage,
Ostas OA therapeutic agent has the potential of
inhibiting cartilage degeneration and promoting
cartilage regeneration. X-Linked
Hypophosphatemic rickets (XLH) No cure exists
for XLH at present. XLH being a rare disease, the
drug for treating XLH is eligible for orphan drug
status and hence an expedited review with
significantly shorter regulatory development
time. Osta is developing novel therapeutic agents
that could be used to treat XLH.
Partners/Strategic Alliances Jewish General
Hospital, McGill University, Queens University,
Helsinki University, Finland. Other partnerships
and potential licensing deals under discussion.

Osta Biotechnologies Inc. 179 Choquette,
Dollard-des-Ormeaux Quebec H9A 3H2,
Canada www.ostabiotechnologies.com
Investor relations contact Mr. Alain
Geahchan a.geahchan_at_ostabiotechnologies.com Phone
514-481-7521 Mobile [phone]